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1. Introduction 
Bipolar disorder is a mood disorder that is characterized by episodes of mania or 
hypomania that often alternate with episodes of depression. Bipolar disorder is also referred 
to as manic-depressive disorder and bipolar affective disorder. This potentially disabling 
mood disorder has a lifetime prevalence of 4% in the US population (Ketter, 2010). 
According to the National Institute of Mental Health (NIMH), bipolar disorder is classified 
as severe in 82.9% of adult patients, with 25 being the average age of onset. As is the case 
with the majority of psychiatric disorders, bipolar disorder tends to run in families (Smoller 
and Finn, 2003).  
Bipolar disorder varies in its presentation and may be difficult to diagnose. Diagnosis 
requires the presence of a manic or a hypomanic episode; however, it is likely that the first 
few episodes may present as bouts of  depression, particularly in younger patients 
(Saddock and Saddock, 2003). According to the Diagnostic and Statistical Manual of 
Mental Disorders fourth edition (DSM-IV-TR; American Psychiatric Association, 2000) a 
distinct period of abnormal mood for at least one week is required to meet diagnostic 
criteria.  
There are two major subtypes of bipolar disorder: type I and type II. Type I requires the 
presence of at least one manic or mixed episode. Mania is categorized by euphoria, 
impulsivity, distractibility, racing thoughts, irritability, decreased need for sleep and 
grandiosity. Individuals with mania may stay up all night cleaning or working on 
flamboyant projects, or they may engage in large spending sprees, gambling or substance 
abuse. Manic individuals often exhibit pressured speech which may be loud, verbose, and 
intrusive in nature. The thought process in mania is often disorganized with flight of ideas 
and loosening of associations. Manic individuals often have poor judgment and insight and 
they are likely to give unreliable case histories  (Saddock and Saddock, 2003).  
Manic episodes may vary in severity, with the more severe cases involving psychosis. About 
75% of manic individuals experience some form of perceptual disturbance (Saddock and 
Saddock, 2003). Psychotic features of manic individuals are characterized by the presence of 
hallucinations and or delusions. These features may be congruent with the mood and may 
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revolve around possession of knowledge or power, disturbance in identity or belief in 
having relationship to a deity or famous person. Mood-incongruent psychotic symptoms do 
not focus on the themes mentioned above and are more likely to include thought insertion 
and delusions of being persecuted or controlled (Saddock and Saddock, 2003). Individuals 
suffering from bipolar disorder I may also experience mixed episodes. Mixed episodes often 
combine characteristics of a depressive episode with irritability, anxiety or inner tension, 
psychomotor agitation and racing thoughts (Koukopoulos and Koukopoulos, 1999; Ketter, 
2010). Individuals experiencing mixed episodes are at highest risk for suicide, secondary to 
increased irritability and impulsivity combined with depressed mood (Goldberg et al., 1998; 
Akiskal and Benazzi, 2005).  
Unlike bipolar I, bipolar disorder type II does not include full-blown manic episodes and 
it is often defined by episodes of hypomania combined with features of major depression 
and is considered to be less severe than bipolar I (Goodwin and Jamison, 1990). According 
to the DSM-IV-TR, hypomania is characterized by persistently elevated, irritable, or 
expansive mood lasting at least 4 days (as opposed to at least one week for mania). This 
mood must be distinct from the usual (nondepressed) mood. Although the mood 
disturbance in a hypomanic individual is observable by others, hypomanic episodes are 
not severe enough to cause marked impairment in social or occupational functioning, or 
to necessitate hospitalization (American Psychiatric Association, 2000). Additionally, 
psychotic features are absent from hypomania. Both mania and hypomania may be 
caused by comorbid states, such as hyperthyroidism or other medical conditions, 
hypothyroidism, electroconvulsive therapy (ECT) and medications such as 
antidepressants. In these cases, a diagnosis of bipolar disorder may not be established 
since diagnosis requires that the symptoms must not be due to a general medical 
condition or direct physiologic effects of a substance. 
In bipolar disorder, episodes of mania or hypomania may alternate with episodes of 
depression. Episodes of depression are not exclusively limited to bipolar II and may also be 
present in bipolar I disorder. Depressive episodes involve either dysphoria (depressed 
mood) or anhedonia (loss of interest in pleasure). A major depressive episode is 
characterized by sadness or depressed mood, sleep disturbances (insomnia or 
hypersomnia), appetite disturbances, changes in body weight, suicidality, feelings of 
helplessness, hopelessness, worthlessness or guilt, loss of energy and loss of interest in 
activities (Saddock and Saddock, 2003). Individuals in a depressed episode may appear to 
be withdrawn and may exhibit slowing down of mental processes, known as psychomotor 
retardation. Not all depressed individuals admit to feeling depressed but they usually 
exhibit a negative outlook (Saddock and Saddock, 2003). During a depressive episode, 
patients may experience psychotic features such as hallucinations and or delusions. Patients 
in a depressed episode may also experience problems with memory and cognition. They 
may have problems concentrating or remembering recent events. Patients in a depressed 
episode are particularly at risk for suicide, with about 2/3 of them experiencing suicidal 
ideations (Saddock and Saddock, 2003). Comorbid states such as hypothyroidism and 
alcohol abuse may precipitate depression. 
Bipolar disorder falls on a spectrum of severity. A less severe form is known as 
cyclothymia, which is characterized by cyclical mood swings that are less severe than full-
blown mania or depression. Cyclothymia may involve hypomania but does not cause 
marked impairment in functioning and often involves a euphoric phase and a dysthymic 
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phase. The DSM-IV-TR criteria for rapid cycling include at least four episodes within a 12 
month period. Patients with rapid cycling are more likely to be female and to have 
depressive and hypomanic episodes (Saddock and Saddock, 2003). At times, the 
presentation of bipolar disorder may not fit into any specific category and therefore will 
be classified as unspecified. 
Bipolar disorder is a progressive illness, in which frequency of episodes increases over 
time with subsequent decreased probability of treatment response (Berk et al., 2010). 
Individuals suffering from bipolar disorder have been shown to have altered reward 
processing (Pizzagalli et al., 2008). Bipolar manic patients were observed to produce more 
errors in a two-choice selection task, suggesting impairment in making decisions during 
times of uncertainty about the success of the outcome (Minassian et al., 2004). Response-
reversal studies involving medicated euthymic children with bipolar disorder showed 
that these children were slower to learn variable stimulus-reward contingencies (Gorrindo 
et al., 2005). Additionally, manic bipolar patients were observed to make more 
unfavorable choices when presented with two choices of variable favorability (Murphy et 
al., 2001). Both symptomatic and euthymic bipolar patients have been noted to 
demonstrate a decreased bias response toward more frequently rewarded stimuli, with 
anhedonic patients showing greater impairments in reward learning (Pizzagalli et al., 
2008). The implication is that bipolar patients may have impairment in the long-term 
integration of reinforcements and may struggle with adapting their behavior to alterations 
in reward (Pizzagalli et al., 2008).  
2. Neuroanatomy and bipolar disorder 
Regulation of mood is believed to involve primarily two major neuroanatomic circuits: 
the limbic-thalamic-cortical circuit and the limbic-striatal-pallidal-cortical circuit 
(Mayberg, 1997; Soares and Mann, 1997). The limbic-thalamic-cortical circuit is also 
involved in working memory and includes the medial-dorsal nucleus of the thalamus, 
the ventrolateral prefrontal cortex and the amygdala (Floresco et al., 1999; Parsey et al., 
2006). The limbic-striatal-pallidal-cortical circuit is involved in emotional expression 
(Drevets et al., 2008). Dysfunction in either of these circuits may result in a mood 
disorder (Parsey et al., 2006). Neuroanatomical changes of patients affected by bipolar 
disorder have been associated with a dysfunction in the prefrontal cortex, basal ganglia, 
temporal and frontal lobes of the forebrain as well as parts of the limbic system including 
amygdala, thalamus and striatum (Cerullo et al., 2009). Patients with bipolar disorder 
have also been found to have abnormalities in the subgenual anterior cingulate cortex 
(sACC) (Shah et al., 2009; Rosen and Rich, 2010). More specifically, decreased glial cell 
volume, regional cerebral blood flow, and decreased glial cell number have been 
observed in this region in bipolar patients, as opposed to healthy controls (Drevets et al., 
1997; Ongur et al., 1998). Increased limbic activity has been found to be associated with 
aberrant emotional processing while neurophysiological abnormalities in the prefrontal 
cortex have been associated with impaired executive function (Green et al., 2007). 
Dysfunction in the prefrontal cortex, basal ganglia and the limbic system plays a 
significant role in bipolar disorder due to the strong connection between these regions 
and the emotional and cognitive aspects of affect regulation (Papez J.W., 1937; Allman et 
al., 2001; Vogt BA, 2005).  
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The nature and location of the neuroanatomical dysfunction in bipolar patients often correlates 
with the resulting symptoms. Abnormalities in the frontosubcortical circuit, especially in the 
hippocampus and the prefrontal cortex, may explain the attention impairment observed in 
manic patients (Sax et al., 1999). Reduced neuronal and glial density and glial hypertrophy 
have been identified in the hippocampus and the dorsolateral prefrontal cortex of patients 
with bipolar disorder (Rajkowska et al., 2001). These observations may account for cell loss 
observed in brain imaging and post-mortem studies of bipolar patients (Brown et al., 2003). 
These deficits differ from reported observations of increased neuronal density noted in 
patients with schizophrenia. The specific pattern of cell loss described above appears to 
resemble the reduced cell density found in patients with major depressive disorder 
(Rajkowska et al., 2001; Brown et al., 2003). Patients with bipolar disorder have less reduction 
of hippocampal volume than schizophrenic patients (Radonic et al., 2011). The hippocampus, 
particularly the CA3 region, plays an important role in the formation of declarative memory, 
which requires separate encoding of elements of an event and their organization in relation to 
one another (Preston et al., 2005). Impairment in the circuitry involved in formation of this 
type of memory may be responsible for the observed impairment in spatial memory and 
reward processing that has been noted in bipolar patients. 
Individuals with bipolar disorder appear to exhibit altered responses to emotional stimuli, 
with apparent dysfunction in the ventral-limbic regions including the ventrolateral 
prefrontal cortex, the orbitofrontal cortex, the subgenual cingulate cortex, the insula, 
amygdala and striatum (Wessa and Linke, 2009). Dysfunction in the fronto-striatal-limbic 
network, which includes the structures mentioned above, has been associated with aberrant 
emotional processing, particularly with regard to misreading facial expression of emotions 
(Rosen and Rich, 2010). Increased striatal activity has been reported in bipolar patients in 
response to potentially rewarding stimuli (Hassel et al., 2008). Additionally, decreased 
activity has been noted in the dorsal brain structures including right dorsolateral prefrontal 
cortex, posterior cingulate cortex, and the dorsal anterior cingulate cortex of patients with 
bipolar disorder following exposure to significant emotional stimuli (Hassel et al., 2008; 
Wessa and Linke, 2009). It appears that imbalance between the ventral-limbic network and 
the dorsal brain structures may be responsible for the emotional dysregulation observed in 
bipolar disorder (Wessa and Linke, 2009). 
Functional magnetic resonance imaging (fMRI) studies have shown a dysfunction of 
subcortical pre-frontal networks (striato-thalamic) and associated regions of the limbic lobe 
(Strakowski et al., 2005). Decreased modulation of medial temporal and subcortical 
structures in the anterior limbic lobe (striatum, amygdala and thalamus) by prefrontal areas 
has been noted to appear early in the course of the illness (Strakowski et al., 2005). The 
amygdala, which plays a role in the regulation of mood, is noted to be decreased in volume 
in bipolar patients. This decrease appears to be more severe as the patients get older (Doty et 
al., 2008), suggesting a correlation between progression of bipolar disorder and increasing 
abnormalities in the brain. Individuals in the early stages of bipolar disorder were found to 
have changes in the volume of the white matter, ventricles, amygdala, caudate nucleus, 
subgenual prefrontal cortex and putamen (Hajek et al., 2005). Moreover, the use of lithium 
for mood stabilization in bipolar disorder has been shown to increase the size of the 
amygdala and hippocampus (Yucel et al., 2007; Foland et al., 2008; Yucel et al., 2008). Other 
abnormalities found in the brains of bipolar patients using neuroimaging techniques have 
been noted to appear with recurrent episodes of mood instability and affect dysregulation. 
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These abnormalities have been observed in the lateral ventricles, cerebellar vermis and other 
prefrontal regions such as the left anterior prefrontal cortex (Strakowski et al., 2005). It 
appears that although abnormalities may be present at the onset, the severity of these 
lesions progresses with the disease.  
3. The role of oxidative stress 
Oxidative stress has been shown to play a role in the pathophysiology of bipolar disorder 
(Gawryluk et al., 2011). Alterations in oxidative enzymes as well as increased lipid 
peroxidation products and reactive oxygen species have been detected in individuals with 
bipolar disorder and other psychiatric diseases (Steckert et al., 2010). Reduced levels of 
glutathione in the brain have been reported in bipolar disorder as well as schizophrenia 
(Fullerton et al., 2010; Dean et al., 2011; Magalhaes et al., 2011). Along with glutathione 
reductions, evidence of oxidative damage to mitochondrial proteins have been noted in 
the brains of patients (Andreazza et al., 2010; Gawryluk et al., 2011). As the primary 
antioxidant in the body, glutathione acts as a free radical scavenger and has been noted to 
be present in high levels in the brain (Choy et al., 2010; Gawryluk et al., 2011). Decreased 
glutathione levels increase susceptibility of cells to oxidative stress (Gawryluk et al., 
2011). Glutathione depletion has been associated with cognitive deficits such as disruption 
in short-term recognition memory and depression in psychiatric illnesses including 
bipolar disorder and schizophrenia (Choy et al., 2010). Glutathione replacement appears 
to improve these deficits. Administration of N-acetyl-cysteine (NAC), which is a 
precursor of glutathione, has been associated with improved short-term spatial memory 
in rats and with depression in humans (Choy et al., 2010; Magalhaes et al., 2011). 
Moreover, antioxidant effects of mood stabilizers including lithium and valproic acid 
have been observed in animal models of oxidant-induced mania (Jornada et al., 2011). 
These findings further support the role of oxidative stress in bipolar disorders while 
emphasizing the protective effects of mood stabilizers with regard to their proposed 
antioxidant effects on the brain. 
4. Cortisol and HPA axis 
There is a general consensus that the hypothalamic-pituitary-adrenal (HPA) axis plays a 
significant role in the pathophysiology of bipolar disorders. HPA regulates stress responses 
via stress hormones, including cortisol, adrenocorticotropic hormone (ACTH), corticotropin-
releasing hormone (CRH) and arginine vasopression (AVP). CRH is released by hypothalamic 
neurons into the portal circulation and stimulates the release of ACTH from the anterior 
pituitary. Studies have found an enhanced response to CRH in bipolar manic individuals as 
compared to controls (Vieta et al., 1999). CRH stimulation has been shown to result in 
dysregulation of ACTH and cortisol response in bipolar disorder, leading to HPA axis 
dysregulation and altered cortisol release (Daban et al., 2005). The severity of both manic and 
depressive symptoms appears to correlate with the severity of HPA dysfunction (Daban et al., 
2005). Interestingly, the changes in CRH secretion appear before symptoms become evident in 
bipolar individuals (Daban et al., 2005).  
Increased HPA axis activity has been associated with depression, mixed manic states and 
less commonly with true manic episodes (Garlow S, 1999; Varghese and Brown, 2001; Manji 
et al., 2003). Elevated daytime cortisol levels were observed in the offspring of parents with 
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mood disorders, suggesting that cortisol excess may serve as a biomarker for susceptibility 
to developing bipolar disorder (Ellenbogen et al., 2011).  
Since some of the morphological changes associated with chronic stress respond to mood 
stabilizers, chronic stress is believed to affect the development and progression of bipolar 
disorder (Wood et al., 2004). The complete evaluation of the extensive amount of data 
regarding the effects of chronic stress on brain morphology would certainly exceed the 
scope of the present chapter. Studies examining the human brain via MRI have noted 
decreased hippocampal volume in patients with post traumatic stress disorder (PTSD) and 
Cushing’s syndrome, which are both conditions associated with excess cortisol levels (Manji 
et al., 2003). Of particular importance is the atrophy of CA3 hippocampal neurons which 
have been exposed to high levels of glucocorticoids (Sapolsky, 2000). Studies revealed that 
remodeling of apical dendrites on hippocampal CA3 pyramidal cells is mediated by adrenal 
steroids and excitatory amino acids (Wood et al., 2004). The threshold for cellular atrophy 
and death may be lowered by various pathological and physiological events including 
excitotoxicity from abnormal glutamatergic signaling enhancement and inhibition of glucose 
transport (Sapolsky, 2000). More importantly, these changes have been observed to be 
reversible and may even be prevented to some degree by pharmacological treatment with 
mood stabilizers (Wood et al., 2004).  
5. Neurotransmitters involved in bipolar disorder 
5.1 Norepinephrine 
The dysfunctional behavior and mood dysregulation observed in mood disorders often 
involves abnormal neurotransmitter function. Monoamines are a class of neurotransmitters 
including dopamine, norepinephrine, epinephrine and serotonin. Neurochemical 
abnormalities involving monoamines have been observed in patients with bipolar disorder 
(Goodwin and Jamison, 1990; Fibiger, 1991; Willner et al., 1991; Schatzberg and Schildkrout, 
1995; Manji H. and Potter W., 1997). Increased concentrations of norepinephrine have been 
found in the plasma and cerebrospinal fluid (CSF) of patients with bipolar mania (Goodwin 
and Jamison, 1990; Manji H. and Potter W., 1997). Increased norepinephrine turnover has also 
been noted in the thalamic and cortical areas in post mortem studies of individuals with 
bipolar disorder (Young et al., 1994; Vawter et al., 2000). On the other hand, norepinephrine 
was observed to be reduced to normal resting output in bipolar depressed patients (Manji and 
Lenox, 2000). In vivo studies have additionally revealed lower plasma levels of norepinephrine 
and its major metabolite, 3-methoxy-4-hydroxyphenylglycol (MHPG) in patients with bipolar 
depression as opposed to those with unipolar depression (Manji H. and Potter W., 1997). 
Urinary excretion of MHPG has also been noted to be higher in the manic state in comparison 
to the depressed state (Manji et al., 2003). The rate of norepinephrine turnover appears to be 
inversely proportional to the degree of depression, with higher turnover observed in more 
manic states. An explanation for this phenomenon may involve alteration in sensitivity of ┙2 
and ┚2 adrenergic receptors in people with mood disorders (Schatzberg and Schildkrout, 
1995). These observations suggest that bipolar individuals may be hypersensitive to 
fluctuations of norepinephrine levels, similarly to the noted hypersensitivity to acetylcholine in 
bipolar patients. Alterations in ┙2 autoreceptor sensitivity may lead to increased activity of the 
┙2 autoreceptor, resulting in decreased release of norepinehprine, which subsequently affects 
mood (Manji and Lenox, 2000; Delgado and Moreno, 2000).  
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5.2 Dopamine 
Dopamine is a catecholamine that has been shown to play a significant role in bipolar 
disorders (Cousins et al., 2009). Excess dopamine activity facilitates mania and delusional 
symptoms (Manji H. and Potter W., 1997; Serretti et al., 2001; Wightman and Robinson, 
2002). Dopamine has also been proposed to play a role in the etiology of bipolar disorder. 
Manic states in healthy individuals that have received substances that increase 
dopaminergic activity (L-DOPA [the dopamine precursor L-3,4-dihydroxyphenylalanine], 
bromocryptine and amphetamine) have been observed (Murphy et al., 1971; 
Szczepankiewicz et al., 2011). Additional observations include the presence of manic 
symptoms following administration of high dose dopamine precursors to individuals with 
Parkinson’s disease, with subsequent depressive state upon withdrawal of the dopamine 
precursor (Berk et al., 2007). Deficiency of dopamine has been suspected to play a role in the 
pathophysiology of depression. Reduced levels of homovanillic acid (HVA), a 
catecholamine metabolite that has been associated with dopamine, have consistently been 
found in the CSF of depressed and suicidal patients (Roy et al., 1992; Young et al., 1994; 
Manji H. and Potter W., 1997). These findings suggest that decreased neurotransmission of 
dopamine may correlate with depression and suicidality supporting the theory of 
catecholamine withdrawal in depressive states of bipolar disorder. It appears that dopamine 
excess correlates with manic states while dopamine depletion or withdrawal may 
precipitate depression. It has been suggested that the cyclical nature of bipolar disorder may 
result from potential downregulation of dopamine receptor sensitivity following excessive 
dopamine secretion (Berk et al., 2007).  
Dopamine neurotransmission is primarily regulated by reuptake of dopamine from the 
synapse by the dopamine transporter (DAT) (Anand et al., 2011c). Dopamine binds to G 
protein-coupled receptors (D1, D2, D3, D4, D5), which then mediate its function in the 
nervous system (Beaulieu and Gainetdinov, 2011). The mechanism involving the DAT has 
been used as a marker for presynaptic dopamine function and has been found to be 
dysfunctional in individuals with bipolar disorder (Anand et al., 2011b). Significantly lower 
DAT availability has been found in the striatum of bipolar patients as opposed to healthy 
controls (Anand et al., 2011a). Animal studies revealed manic behavior traits such as 
increased risk-taking behavior in mice with reduced DAT function (Young et al., 2011), 
suggesting that reduced availability of the DAT results in subsequent increase in synaptic 
dopamine which therefore facilitates mania (Fig.1).  
The pivotal role of dopamine in the pathomechanism of the bipolar disorders is supported 
by the observation that excessive dopamine levels observed in mania can be effectively 
treated with antipsychotic medications, whose mechanism involves dopamine blockade 
(Greenwood et al., 2001). Conversely bupropion (Wellbutrin), which binds to the dopamine 
transporter and also inhibits reuptake of norepinephrine, has been shown to be effective in 
treating bipolar depression (Sachs et al., 1994). 
5.3 Serotonin 
Abnormalities in the indolamine serotonin (5-HT) have also been observed in bipolar 
disorder. Studies examining hippocampal 5-HT1A, 5-HT2A, and 5-HT1B mRNA and 5-HT1A 
and 5-HT2A receptor mRNA in the dorsolateral prefrontal cortex have revealed increased 
serotonin mRNA levels and decreased 5-HT2A mRNA levels in the hippocampal formation  
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Fig. 1. The role of dopamine transporter (DAT) in the pathogenesis of mania. 
of bipolar and schizophrenic patients  (Lopez-Figueroa et al., 2004). Studies have found a 
correlation between major depressive episodes and altered serotonergic neurotransmission 
(Maes et al., 1995; Garlow S, 1999). Decreased radioligand binding to the serotonin 
transporter has been noted in the midbrain and platelets of individuals with depression 
(Garlow S, 1999). Reduction in central serotonergic activity has been found in bipolar 
individuals who were in the depressed phase, with similar findings in euthymic bipolar 
patients (Mahmood and Silverstone, 2001; Chou et al., 2010). Further studies reported 
decreased 5-HT1A receptor binding in the hippocampus, amygdala and raphe in bipolar 
depressed patients, depressed relatives of bipolar patients as well as other individuals 
suffering from depression (Drevets et al., 1999). However, increased levels of 5-HT1A were 
noted in depressed males with bipolar disorder (Sullivan et al., 2009). These findings 
indicate an increase in autoreceptor binding which may lead to decreased release of 
serotonin with a subsequent upregulation of postsynaptic 5-HT1A receptors (Sullivan et al., 
2009). Increased cortisol secretion has been proposed as one explanation for the decrease in 
5-HT1A receptor binding in depressive states, particularly since stimulation of corticosteroid 
receptors has been associated with inhibition of postsynaptic 5-HT1A receptor mRNA 
expression in some regions of the brain (Manji et al., 2003). These data support the 
observation that the onset of bipolar symptoms and recurrence of manic and depressive 
episodes are more likely to occur during times of stress.  
Models involving tryptophan depletion have further explored the role of serotonin in 
bipolar disorder. Tryptophan depletion lowers the levels of serotonin (Manji et al., 2003) and 
associated with recurrence of depression secondary to a reversed response to antidepressant 
medications in patients with a mood disorder but no onset or worsening of depression in 
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nonmedicated depressed patients, healthy individuals without mental illness or in lithium-
treated euthymic patients with bipolar disorder (Delgado et al., 1999; Hughes et al., 2000). 
Research has examined unaffected relatives of patients with bipolar disorder in order to 
investigate if sensitivity to cognitive effects of serotonin decrease might serve as a heritable 
marker or endophenotype for bipolar disorder (Manji et al., 2003). One double-blind 
crossover design study examined 20 unaffected relatives of bipolar patients and 19 control 
subjects undergoing acute tryptophan depletion (ATD). The study revealed that unaffected 
relatives of bipolar patients exhibited increased impulsivity and depressed mood following 
ATD as opposed to placebo (Sobczak et al., 2002). These symptoms were not observed in 
healthy controls. Additionally, unaffected relatives were found to have decreased number of 
lower affinity binding sites for imipramine and lower platelet concentrations of serotonin 
independent of ATD administration. Further studies revealed impairment in planning and 
memory in first degree healthy relatives of bipolar type I patients independent of ATD as 
well as impaired speed of information processing in first degree healthy relatives but not in 
healthy controls following ATD (Sobczak et al., 2002). These data suggest that impairments 
in serotonin metabolism observed in bipolar patients may be inherited. 
A reduction in the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) was observed 
in patients with bipolar disorder as well as other mood disorders (Young et al 1994). This 
reduction was especially noted in individuals with aggression, impulsivity and suicide 
attempts (Manji et al., 2003). However, data regarding the 5-HIAA levels in manic versus 
depressed individuals is rather controversial. Some studies did not find a difference in CSF 
5-HIAA levels between manic and depressed patients (Goodwin and Jamison, 1990), while 
others noted decreased 5-HIAA in the CSF in both manic and depressed individuals 
compared to controls as well as a significant decrease in CSF 5-HIAA accumulation in manic 
individuals as compared to their depressed counterparts and to controls (Goodwin and 
Jamison, 1990). Despite the inconsistent results, decreased CSF levels of the serotonin 
metabolite 5-HIAA appear to correlate with impulsive, aggressive behavior and mania, 
emphasizing the role of serotonin in the pathophysiology of bipolar disorder.  
5.4 Glutamate 
Abnormalities in glutamate and glutamate receptor functioning have been noted in patients 
with bipolar disorder. Glutamate is a major excitatory neurotransmitter affecting cognition, 
learning and memory (Shigeri et al., 2004). While glutamate mediates information affecting 
cellular survival, formation and destruction of synapses and brain development, it may be 
neurotoxic if not present in the right concentrations at appropriate locations and time in the 
nervous system (Danbolt, 2001). Stress-induced hippocampal changes in the brains of 
patients with bipolar disorder have been noted to include alterations in glutamate and its 
receptors. Patients with bipolar disorder have been found to have elevated lactate and 
glutamate levels (Dager et al., 2004). Elevated glutamate levels have been noted particularly 
in the dorsolateral prefrontal cortex of patients with acute mania (Michael et al., 2003). 
Elevated glutamate neurotransmission has been reported in bipolar patients and has been 
suggested as the reason for elevated glutamate levels in the cortex (Eastwood and Harrison, 
2010). More specifically, increased expression of the vesicular glutamate transporter 
(VGluT1), which is expressed in glutaminergic neurons, has been found in the anterior 
cingulate cortex of bipolar patients (Eastwood and Harrison, 2010). VGluT1, netrin-G1 and 
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its isoforms Gqc, G1d and G1f, as well as netrin-G2 are axon guidance and cellular adhesion 
molecules (Eastwood and Harrison, 2010). They participate in formation and maintenance of 
glutamatergic synaptic connections (Eastwood and Harrison, 2010). Netrin–G expression 
was also found to be elevated in the right anterior cingulate cortex of bipolar patients 
(Eastwood and Harrison, 2010). Netrin-G molecules have been known to affect the 
formation and plasticity of excitatory pathways (Eastwood and Harrison, 2010), suggesting 
that their increased expression may lead to increase in glutamate neurotransmission and 
possible neurotoxicity in the brains of bipolar patients.  
5.5 GABA 
Abnormal levels of gamma amino butyric acid (GABA) have been identified in bipolar 
disorder. GABA is an inhibitory neurotransmitter which modulates the activity of other 
neurotransmitters in the central nervous system (Vuoristo J, 2011). It is synthesized from 
glutamate, with the enzyme glutamate decarboxylase playing a key role in its synthesis 
(Bielau et al., 2007) (Fig.2). GABA plays a role in modulating hippocampal and cortical 
circuits and is involved in discriminative information processing, integrating sensory 
information and generating oscillatory rhythms in the corticolimbic system (Sakai et al., 
2008). GABA participates in the inhibition of aggressive and impulsive behaviors, which are 
often prevalent in bipolar disorder, particularly in mixed and manic states (Sakai et al., 
2008). GABA deficits as well as decreased inhibitory activity have been reported in the 
cortex of individuals with bipolar disorder (Duffy et al., 2000; Levinson et al., 2007). 
Aberrant modulation of GABA interneurons by glutamate has been noted to occur via the 
NR2A subunit of the N-methyl-D-aspartate (NMDA) receptor in the cerebral cortex (Woo et 
al., 2004). Decreased NR2A mRNA has been observed in bipolar patients, particularly in 
layer 2 of the anterior cingulate cortex (Woo et al., 2004). Decreased plasma levels of GABA 
have also been implicated in bipolar mania as well as in bipolar depression (Petty, 1995). 
Animal studies have revealed decreased GABA function in states of depression with 
subsequent improvement in mood following administration of GABA agonists (Petty, 1995). 
Interestingly, it has been reported that GABA levels do not normalize following treatment 
or remission of depression (Duffy et al., 2000). Post mortem studies examining GABA in 
humans noted significantly decreased protein in GABAb receptor subunits (BABBR1 and 
GABBR2) in the cerebellum of individuals with schizophrenia, bipolar disorder, autism and 
depression as compared to healthy controls (Fatemi et al., 2011). It appears that these deficits 
may be treatable as various classes of antidepressants have been reported to cause an up-
regulation of GABAb receptors (Duffy et al., 2000). Additionally, mood stabilizing 
medications such as valproate, carbamazepine, gabapentin, and lithium carbonate have 
been noted to alter GABA levels, possibly decreasing aggressive and impulsive behavior by 
increasing availability and efficacy of GABA (Sakai et al., 2008). 
5.6 Substance P 
Substance P is a neuropeptide that is widely distributed throughout the central and 
peripheral nervous system (Pioro et al., 1990; Dudas and Merchenthaler, 2002; Lieb et al., 
2003) and it has been shown to play a role in the pathomechanism of bipolar disorder (Lieb 
et al., 2003). Substance P regulates the release of acetylcholine in the cortex and co-localizes 
with dopamine in the midbrain and striatum, with GABA in the cortex, and with serotonin  
www.intechopen.com
 
Bipolar Disorder: Diagnosis, Neuroanatomical and Biochemical Background 
 
177 
 
Fig. 2. Role of GABA in the pathogenesis of mania. 
in the raphe nuclei (Jakab et al., 1997). Substance P, along with its receptor, the neurokinin 1 
receptor (NK1R), is distributed in numerous areas of the brain including hippocampus, 
amygdala, frontal cortex and hypothalamus, and it appears to be involved in regulating 
responses to stress and fear (Herpfer and Lieb, 2005). Alterations of substance P content in 
these regions have been noted to influence the stress response and affective states (Lieb et 
al., 2003). Administration of substance P produces fear-related behaviors while blockade of 
NK1/2R or NK1/2/3R is associated with anxiolytic effects (Herpfer and Lieb, 2005). 
Moreover, an antidepressant effect has been noted when using substance P receptor 
antagonists, such as L-759274 and MK-869 (Mendlewicz et al., 2005). Substance P facilitates 
synthesis of interleukin-6 (IL-6), a cytokine, whose levels have been reported to be elevated 
in acute depressive states of bipolar disorder (Lieb et al., 2003). Inhibition of substance P as 
well as NK1R down-regulation has been noted following valproic acid administration (Lieb 
et al., 2003). 
5.7 Acetylcholine 
Acetycholine, along with cortisol, monoamines and amino acids has been suggested to play 
a role in the pathophysiology of bipolar disorder (Chen et al., 2010). Several studies reported 
catecholaminergic and cholinergic imbalance in bipolar patients. Administration of 
cholinomimetic agents and cholinesterase inhibitors reduced manic symptoms in bipolar 
manic patients (Davis et al., 1978; Fritze and Beckmann, 1988). Indeed, administration of the 
cholinergic agent physostigmine has been shown to result in decrease of manic symptoms in 
manic individuals as well as increase in depressive symptoms in non-manic individuals 
(Janowsky et al., 1974; Fritze and Beckmann, 1988). Animal models have noted exaggerated 
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neuroendocrine and behavioral responses in response to administration of cholinergic 
agents (Overstreet et al., 1988; Janowsky et al., 1994). Moreover, rats bred for cholinergic 
sensitivity were noted to be more aggressive (Pucilowski et al., 1990). It appears that 
individuals with bipolar disorder may be more sensitive to the effects of acetylcholine. 
Studies involving humans have noted increased sensitivity to the effects of physostigmine 
administration in patients with affective disorders (Oppenheim et al., 1979; Risch et al., 
1981). More specifically, euthymic patients with bipolar disorder were noted to become 
depressed after physostigmine administrations as compared to healthy controls 
(Oppenheim et al., 1979). Interestingly, previous data also reported  increased serum 
epinephrine levels following administration of a cholinergic agent, suggesting that increased 
cholinergic tone may precipitate a subsequent increase in adrenergic tone  (Janowsky et al., 
1986).  
6. The role of genes 
According to the kindling theory, the likelihood of developing bipolar disorder increases in 
response to a series of stressful events in predisposed individuals (Saddock and Saddock, 
2003). Studies involving adoption, twins and family reveal a genetic predisposition to 
developing bipolar disorder (Gershon et al., 1990; Muglia et al., 2002). A multitude of genes 
interacting with each other as well as with the environment is most likely lead to a 
multifactorial mode of inheritance for bipolar disorder (Berrettini W.H, 1999; Muglia et al., 
2002). A significant association was reported between two single nucleotide polymorphisms 
(rs4952 and rs4953) in the human beta 3 nicotinic acetylcholoine receptor subunit gene 
(CHRNB3) on chromosome 8 and bipolar disorder (Hartz et al., 2011). Additionally, genetic 
linkage studies suggest a role for human alpha7 nicotinic acetylcholine receptor subunit 
gene (CHRNA7) on chromosome 15q13-q14 as one of the candidate genes for bipolar 
disorder (Hong et al., 2004). Interestingly, linkage to CHRNA7 has also been reported in 
schizophrenia and schizoaffective disorder, suggesting a similar genetic cause for these two 
disorders (Leonard et al., 2001; Martin et al., 2007). Other studies examining chromosome 15 
have found a genetic association between bipolar disorder and GABA-A receptor ra5 
subunit gene locus (GABRA5) on chromosome 15q11-q13 (Otani et al., 2005). Low GABA 
function has been proposed to be a heritable marker for susceptibility to developing a mood 
disorder and GABRA5  may be associated with bipolar disorder (Petty, 1995; Papadimitriou 
et al., 2001). 
Variants in the interleukin-1 (IL-1) cluster on chromosome 2q13 has also been associated 
with increased risk for both schizophrenia and bipolar disorder (Papiol et al., 2008). Specific 
genetic polymorphisms of the IL-1B gene from the IL-1 gene cluster have been associated 
with grey matter deficits in the brain of bipolar disorder patients (Papiol et al., 2008). 
Altered or increased expression of proinflammatory genes has been reported in monocytes 
of individuals with bipolar disorder as well as their offspring (Padmos et al., 2008). This 
pattern of gene expression is a possible etiological cause for the increased oxidative state 
reported in bipolar disorder. 
The short arm of chromosome 11 has been investigated for possible genetic factors leading 
to developing bipolar disorder. This particular region incorporates the tyrosine hydroxylase 
(TH) and the dopamine D4 receptor gene (DRD4) (Todd et al., 1996; Oruc et al., 1997; 
Furlong et al., 1999; Li et al., 1999; Serretti et al., 2001). Tyrosine hydroxylase plays a 
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significant role in the formation of dopamine since it is the key and rate-limiting enzyme of 
the catecholamine synthesis converting tyrosine to DOPA, a precursor of dopamine (Muglia 
et al., 2002). DRD4 has been noted to be highly polymorphic, consisting of 2-10 tandem 
repeats in the third exon, encoding the receptor’s longest loop (Asghari et al., 1995; Muglia 
et al., 2002). The gene for tyrosine hydroxylase contains a microsatellite known as 
HUMTH01, which has been proposed to play a regulatory role in its expression (Meloni et 
al., 1998). Studies investigating the short arm of chromosome 11 have been inconsistent, 
with many of them reporting lack of evidence for association with DRD4 and development 
of bipolar disorder (Byerley et al., 1992; Sidenberg et al., 1994; Smyth et al., 1996; Malafosse 
et al., 1997). Likewise, a positive and negative association has been observed between 
HUMTH01 and bipolar disorder (Serretti et al., 2000; Muglia et al., 2002). Studies examining 
a sample of nuclear families of bipolar patients and their biological parents reported a 
parent of origin effect (POE) for the DRD4 alleles 2- and 4- repeat alleles, which was 
inherited from the mother. This effect was noted to be located on chromosome 11p15.5, 
which is close to a group of imprinted genes (Muglia et al., 2002), indicating that genomic 
imprinting may be associated with bipolar disorder. 
The dopamine transporter (DAT) gene plays a vital role in transmission of dopamine by 
mediating dopamine uptake into the synaptic terminal (Greenwood et al., 2001). Increased 
dopamine concentrations have been observed after administration of cocaine and 
amphetamine, which have been proposed to act at the DAT to inhibit reuptake of dopamine 
(Giros et al., 1992). Studies examining DAT for linkage to bipolar disorder in families from 
the Old Order Amish, Icelandic pedigree and the general North American population 
revealed a locus on chromosome 5p15.3 near the DAT gene, suggestive of autosomal 
dominant inheritance of bipolar disorder (Kelsoe et al., 1996; Homer et al., 1997). More 
specifically, data suggest that a functional variant of a 3’ noncoding sequence element may 
influence susceptibility for bipolar disorder (Greenwood et al., 2001). The significance of 
DAT in bipolar disorder is based on its involvement in regulating synaptic reuptake of 
dopamine (Kelsoe et al., 1996). Chromosomal aberration near the DAT gene locus in bipolar 
patients correlates with abnormalities in dopamine neurotransmission observed in bipolar 
disorder indicating a genetic predisposition to developing the disorder.  
Dysregulation of the serotonin transporter and abnormalities in serotonin metabolism have 
also been noted in studies of patients with affective disorders. Serotonin transporter is 
involved in serotonin regulation and is the site of action for numerous antidepressants 
(Kelsoe et al., 1996). It is noteworthy that  the serotonin transporter polymorphism (5-
HTTLPR) gene as well as brain-derived neurotrophic factor (BDNF) polymorphism have 
been linked with suicidality in bipolar patients (Vincze et al., 2008). The 5-HTTLPR variant 
is the promoter region of the serotonin transporter gene, which has two alleles: the long ‘l’ 
allele and the short ‘s’ allele (Neves et al., 2008). The short ‘s’ allele of the 5-HTTLPR has 
been associated with significantly lower activation of the ventral anterior cingulate cortex, a 
dysfunction observed in bipolar patients (Shah et al., 2009). In addition to its link to bipolar 
disorder, ‘s’ allele is particularly associated with suicidal behavior (Neves et al., 2008; 
Ferreira et al., 2009). Interestingly, mania and suicidality have been repeatedly observed in 
bipolar individuals following treatment with antidepressants (Ferreira et al., 2009). Since 
depression is often treated by selective serotonin reuptake inhibitors (SSRIs), understanding 
this mechanism can encourage more careful assessment and diagnosis of bipolar patients. 
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7. Concluding remarks 
Bipolar disorder is a progressive illness which, if left untreated, results in cognitive decline. 
The rate and nature of the progression of the disease varies among individuals. The 
pathology of the bipolar disorder includes a variety of abnormalities in the neuroanatomy, 
endocrine homeostasis, neurotransmitter functions and genes of the patients.  
Reduced hippocampal volume, dysfunction in the prefrontal cortex and limbic system 
observed in patients suffering in bipolar disorder emphasizes the importance of these brain 
regions in the development of the disease. The nature and extent of these neuroanatomical 
changes vary with the presentation, severity, and duration of the disease. While some 
anatomical abnormalities may be present prior to onset of disease, these lesions may become 
more severe with the progression of the disease. Conversely, certain abnormalities may be 
amendable to treatment. Additional factors involved in the development and progression of 
bipolar disorder include abnormal HPA axis function and oxidative stress. Abnormalities in 
neurotransmitter function, including dopamine, norepinephrine, serotonin, GABA, 
acetylcholine, glutamate and substance P have also been observed in bipolar disorder, 
offering the possibility of various avenues of pharmacologic interventions. Genetic 
variations found in bipolar patients indicate a predisposition in the development of the 
disease. The diversity of the factors involved in the pathomechanism of bipolar disorder 
may explain the wide variety of clinical manifestations and consequently may offer a broad 
range of options for successful treatment of this debilitating disease. 
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